Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
The investigators will test the hypothesis that positron emission tomography (PET) imaging
with the imaging agent 18F-thymidine (FLT) can rapidly assess treatment response in patients
with unresectable non-small cell lung cancer (NSCLC).